Redoxal

Overview

Redoxal is a dihydroorotate dehydrogenase ( DHODH ) inhibitor and anti- HIV-1 agent. Redoxal induces intracellular pyrimidine depletion by inhibiting the de novo pyrimidine biosynthesis pathway, enhances the protein stability of APOBEC3G (A3G) , upregulates the abundance of A3G protein in cells and progeny viral particles, thereby strengthening the host endogenous antiviral restriction mediated by A3G . Redoxal selectively targets DHOdehase at the mitochondrial level, with an IC 50 of 430 nM for inhibiting DHO oxidation in human mitochondria and an IC 50 of 910 nM in rat mitochondria . Redoxal can be used in studies related to HIV-1 infection.

Application

Products | Products > Disease Areas > HIV-1 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > HIV Infection | Products > Disease Areas > Sexually Transmitted Disease | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Signaling Pathways > HIV | Products > Signaling Pathways > Dihydroorotate Dehydrogenase

Product Information

• Catalog No.: HY-183925
• CAS No.: 52962-95-5
• Molecular Formula: C28H24N2O6
• Molecular Weight: 484.50
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source